Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate
CA 2499189 A1 · Owner: University Of South Florida · Inventors: Bhalla, Kapil N.; Nimmanapalli, Ramedevi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for inducing apoptosis, or increasing the rate or extent of apoptosis, in target cells. The method comprises the steps of contacting the cancer cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor imatinib mesylate, and a histone deacetylase inhibitor Suberoylanilide , Hydromaxic Acid (SAHA). The method is applicable to ameliorating the resistance of the accelerated and blast phases of CML (CML-BC) to imatinib mesylate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 19, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 19, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 19, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.